Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cabot (CBT) Research & Development (2016 - 2025)

Cabot (CBT) has disclosed Research & Development for 17 consecutive years, with $13.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development fell 7.14% to $13.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $58.0 million, a 6.45% decrease, with the full-year FY2025 number at $59.0 million, down 6.35% from a year prior.
  • Research & Development was $13.0 million for Q4 2025 at Cabot, down from $15.0 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $17.0 million in Q3 2024 to a low of $12.0 million in Q2 2021.
  • A 5-year average of $14.4 million and a median of $15.0 million in 2021 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: increased 21.43% in 2024, then decreased 11.76% in 2025.
  • Cabot's Research & Development stood at $13.0 million in 2021, then changed by 0.0% to $13.0 million in 2022, then rose by 15.38% to $15.0 million in 2023, then fell by 6.67% to $14.0 million in 2024, then dropped by 7.14% to $13.0 million in 2025.
  • Per Business Quant, the three most recent readings for CBT's Research & Development are $13.0 million (Q4 2025), $15.0 million (Q3 2025), and $15.0 million (Q2 2025).